{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:29:33Z","timestamp":1791836973944,"version":"4.3.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA42012"],"award-info":[{"award-number":["P30 CA42012"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010638","name":"Huntsman Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.wneu.2015.09.060","type":"journal-article","created":{"date-parts":[[2015,10,2]],"date-time":"2015-10-02T02:58:48Z","timestamp":1443754728000},"page":"210-219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies"],"prefix":"10.1016","volume":"86","author":[{"given":"Michael","family":"Karsy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talmadge","family":"Barth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Dunson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy L.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2015.09.060_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson","year":"1957","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.wneu.2015.09.060_bib2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnen\/61.3.215","article-title":"The WHO classification of tumors of the nervous system","volume":"61","author":"Kleihues","year":"2002","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.wneu.2015.09.060_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0090-3019(86)90233-8","article-title":"Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome","volume":"25","author":"J\u00e4\u00e4skel\u00e4inen","year":"1986","journal-title":"Surg Neurol"},{"key":"10.1016\/j.wneu.2015.09.060_bib4","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1634\/theoncologist.2011-0193","article-title":"Update on meningiomas","volume":"16","author":"Saraf","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.wneu.2015.09.060_bib5","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clineuro.2009.12.011","article-title":"Management of meningiomas","volume":"112","author":"Alexiou","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.wneu.2015.09.060_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/107327480301000206","article-title":"New approaches for the treatment of refractory meningiomas","volume":"10","author":"Ragel","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.wneu.2015.09.060_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1227\/01.NEU.0000330399.55586.63","article-title":"Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation","volume":"64","author":"Aghi","year":"2009","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2015.09.060_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1023\/A:1005981731739","article-title":"Atypical and malignant meningiomas: an outcome report of seventeen cases","volume":"39","author":"Coke","year":"1998","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1227\/01.NEU.0000311061.72626.0D","article-title":"Radiosurgery as definitive management of intracranial meningiomas","volume":"62","author":"Kondziolka","year":"2008","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2015.09.060_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:NEON.0000021827.85754.8e","article-title":"Non-resectable slow-growing meningiomas treated by hydroxyurea","volume":"67","author":"Loven","year":"2004","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib11","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1215\/15228517-2009-010","article-title":"Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)","volume":"11","author":"Wen","year":"2009","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11060-011-0741-z","article-title":"Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma","volume":"107","author":"Chamberlain","year":"2012","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib13","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/cncr.23803","article-title":"Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas","volume":"113","author":"Chamberlain","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2015.09.060_bib14","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1212\/01.wnl.0000271382.62776.b7","article-title":"Recurrent meningioma: salvage therapy with long-acting somatostatin analogue","volume":"69","author":"Chamberlain","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2015.09.060_bib15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11060-011-0541-5","article-title":"Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series","volume":"104","author":"Chamberlain","year":"2011","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib16","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1212\/01.WNL.0000118300.82017.F4","article-title":"Temozolomide for treatment-resistant recurrent meningioma","volume":"62","author":"Chamberlain","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.wneu.2015.09.060_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11060-005-9093-x","article-title":"Salvage chemotherapy with CPT-11 for recurrent meningioma","volume":"78","author":"Chamberlain","year":"2006","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib18","doi-asserted-by":"crossref","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","article-title":"Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients","volume":"8","author":"Nunes","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.wneu.2015.09.060_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2010","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib20","first-page":"861","article-title":"Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone","volume":"74","author":"Grunberg","year":"1991","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2015.09.060_bib21","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma","volume":"13","author":"Johnson","year":"2011","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.wneu.2015.09.060_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11060-011-0687-1","article-title":"Phase II study of Gleevec\u00ae plus hydroxyurea (HU) in adults with progressive or recurrent meningioma","volume":"106","author":"Reardon","year":"2012","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-1-4020-6191-2_15","article-title":"Calcium signalling and cancer cell growth","volume":"45","author":"Capiod","year":"2007","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.wneu.2015.09.060_bib24","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nature07203","article-title":"From endoplasmic-reticulum stress to the inflammatory response","volume":"454","author":"Zhang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2015.09.060_bib25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0140-6736(05)64757-5","article-title":"Hydroxyurea for treatment of unresectable meningiomas","volume":"348","author":"Schrell","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.wneu.2015.09.060_bib26","first-page":"845","article-title":"Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway","volume":"86","author":"Schrell","year":"1997","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2015.09.060_bib27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0014-4827(88)90157-7","article-title":"An in\u00a0vivo study on the synchronizing effect of hydroxyurea","volume":"174","author":"Maurer-Schultze","year":"1988","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.wneu.2015.09.060_bib28","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.3171\/FOC-07\/10\/E11","article-title":"Hydroxyurea chemotherapy in the treatment of meningiomas","volume":"23","author":"Newton","year":"2007","journal-title":"Neurosurg Focus"},{"key":"10.1016\/j.wneu.2015.09.060_bib29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11060-004-2337-3","article-title":"Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study","volume":"74","author":"Hahn","year":"2005","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib30","first-page":"341","article-title":"Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma","volume":"97","author":"Mason","year":"2002","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2015.09.060_bib31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/02688690400012392","article-title":"Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up","volume":"18","author":"Newton","year":"2004","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.wneu.2015.09.060_bib32","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1054\/jocn.2001.1019","article-title":"Treatment of high risk or recurrent meningiomas with hydroxyurea","volume":"9","author":"Rosenthal","year":"2002","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.wneu.2015.09.060_bib33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1055\/s-2006-949518","article-title":"Hydroxyurea treatment of meningiomas: a pilot study","volume":"16","author":"Weston","year":"2006","journal-title":"Skull Base"},{"key":"10.1016\/j.wneu.2015.09.060_bib34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0028-3770(04)98326-9","article-title":"Traitement des m\u00e9ningiomes par hydroxyur\u00e9e","volume":"50","author":"Fuentes","year":"2004","journal-title":"Neurochirurgie"},{"key":"10.1016\/j.wneu.2015.09.060_bib35","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1227\/00006123-199502000-00017","article-title":"In\u00a0vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists","volume":"36","author":"Jensen","year":"1995","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2015.09.060_bib36","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0090-3019(01)00444-X","article-title":"Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice","volume":"55","author":"Jensen","year":"2001","journal-title":"Surg Neurol"},{"key":"10.1016\/j.wneu.2015.09.060_bib37","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/00006123-200003000-00032","article-title":"Calcium channel antagonist effect on in\u00a0vitro meningioma signal transduction pathways after growth factor stimulation","volume":"46","author":"Jensen","year":"2000","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2015.09.060_bib38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1227\/01.NEU.0000245597.46581.FB","article-title":"Calcium channel antagonists augment hydroxyurea- and ru486-induced inhibition of meningioma growth in\u00a0vivo and in\u00a0vitro","volume":"59","author":"Ragel","year":"2006","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2015.09.060_bib39","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1073\/pnas.2235846100","article-title":"A\u00a0small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors","volume":"100","author":"Rubin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.wneu.2015.09.060_bib40","first-page":"304","article-title":"A\u00a0novel model of intracranial meningioma in mice using luciferase-expressing meningioma cells. Laboratory investigation","volume":"108","author":"Ragel","year":"2008","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2015.09.060_bib41","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/cncr.23678","article-title":"Hypoxia-regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme","volume":"113","author":"Flynn","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2015.09.060_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199101033240101","article-title":"Tumor angiogenesis and metastasis\u2013correlation in invasive breast carcinoma","volume":"324","author":"Weidner","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2015.09.060_bib43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1023\/A:1026770624783","article-title":"Hydroxyurea chemotherapy for unresectable or residual meningioma","volume":"49","author":"Newton","year":"2000","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib44","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1158\/0008-5472.CAN-06-3822","article-title":"Specific growth rate versus doubling time for quantitative characterization of tumor growth rate","volume":"67","author":"Mehrara","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2015.09.060_bib45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF01050266","article-title":"A\u00a0phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study","volume":"15","author":"Goodwin","year":"1993","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib46","article-title":"Phase II double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma","volume":"20","author":"Grunberg","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.wneu.2015.09.060_bib47","first-page":"891","article-title":"Growth rate of non-operated meningiomas","volume":"255","author":"Zeidman","year":"2008","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.wneu.2015.09.060_bib48","first-page":"248","article-title":"Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in\u00a0vitro and in\u00a0vivo study","volume":"73","author":"Bowles","year":"1990","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2015.09.060_bib49","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/pros.2990190404","article-title":"Effect of calcium and calcium antagonists on 45Ca influx and cellular growth of human prostatic tumor cells","volume":"19","author":"Batra","year":"1991","journal-title":"Prostate"},{"key":"10.1016\/j.wneu.2015.09.060_bib50","first-page":"3617","article-title":"Antiproliferative effect of verapamil alone on brain tumor cells in\u00a0vitro","volume":"48","author":"Schmidt","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.wneu.2015.09.060_bib51","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1593\/neo.10228","article-title":"Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells","volume":"12","author":"Meister","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.wneu.2015.09.060_bib52","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1734-1140(12)70896-4","article-title":"Verapamil-induced autophagy-like process in colon adenocarcinoma COLO 205 cells; the ultrastructural studies","volume":"64","author":"Paj\u0105k","year":"2012","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.wneu.2015.09.060_bib53","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hup.1008","article-title":"Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter?","volume":"24","author":"Clarke","year":"2009","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.wneu.2015.09.060_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/bjc.1986.19","article-title":"Verapamil increases the sensitivity of primary human colorectal carcinoma tissue to vincristine","volume":"53","author":"Ince","year":"1986","journal-title":"Br J Cancer"},{"key":"10.1016\/j.wneu.2015.09.060_bib55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1472-8206.2009.00723.x","article-title":"No effect of CYP450 and P-glycoprotein on hydroxyurea in\u00a0vitro metabolism","volume":"24","author":"Sassi","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.wneu.2015.09.060_bib56","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1124\/jpet.105.097931","article-title":"Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data","volume":"317","author":"Hsiao","year":"2006","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.wneu.2015.09.060_bib57","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00280-006-0334-2","article-title":"The effect of hydroxyurea on P-glycoprotein\/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate","volume":"59","author":"Oostendorp","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.wneu.2015.09.060_bib58","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/187231207781369799","article-title":"PET-evaluated transport of [11C]hydroxyurea across the rat blood-brain barrier\u2013lack of influence of cyclosporin and probenecid","volume":"1","author":"Syvanen","year":"2007","journal-title":"Drug Metab Lett"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875015012279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875015012279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T17:28:40Z","timestamp":1772040520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875015012279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":58,"alternative-id":["S1878875015012279"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2015.09.060","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2015.09.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}